Immunotherapy in myeloma: Why, when and how?

Immunotherapy in myeloma: Why, when and how?

Bibliographic Details
Main Author:	Niels W.C.J. van de Donk
Format:	Article
Language:	English
Published:	Wiley 2018-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000100

Similar Items

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

Immunotherapy in Head and Neck Cancer When, How, and Why?
by: Daniela Pereira, et al.
Published: (2022-09-01)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
by: Jo Caers, et al.
Published: (2018-11-01)

Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma
by: Marian F. Schmitz, et al.
Published: (2014-12-01)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
by: Chloe O'Neill, et al.
Published: (2023-08-01)

MRI of the lung (2/3). Why … when … how?
by: J. Biederer, et al.
Published: (2012-02-01)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
by: Jort J. van der Schans, et al.
Published: (2020-08-01)

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
by: Benedetto Bruno, et al.
Published: (2021-04-01)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
by: Marina Zajec, et al.
Published: (2020-08-01)

Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma
by: Michelle Kinder, et al.
Published: (2021-01-01)

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS
by: Wassilis Bruins, et al.
Published: (2023-08-01)

Calcifediol: Why, When, How Much?
by: Simone Donati, et al.
Published: (2023-04-01)

Surgical Stillness—When, Why, and How?
by: Jacob Rosenberg, et al.
Published: (2019-10-01)

WHEN WHERE WHY & HOW IT HAPPENED /
by: Davison, Michael Worth, editor 649166
Published: (1993)

Abdominal ultrasound : how, why and when /
by: 309648 Bates, Jane A.
Published: (1999)

Breast ultrasound : how, why and when /
by: Dixon, Anne-Marie
Published: (2007)

Mitotic recombination: why? when? how? where?
by: Matthew C LaFave, et al.
Published: (2009-03-01)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)

Autophagy in protists and their hosts: When, how and why?
by: Patricia Silvia Romano, et al.
Published: (2023-12-01)

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
by: Inger S. Nijhof, et al.
Published: (2015-02-01)

Immunotherapy in Multiple Myeloma
by: Cinnie Yentia Soekojo, et al.
Published: (2020-03-01)

ESSKA consensus initiative: why, when and how?
by: Philippe Beaufils, et al.
Published: (2023-01-01)

Preemptive kidney transplantation: why, when, and how?
by: Ana Flávia Moura, et al.
Published: (2022-09-01)

Ultrasound physics and technology : how, why and when /
by: 394541 Gibbs, Vivien, et al.
Published: (2009)

Peripheral vascular ultrasound : how, why, and when /
by: 346114 Thrush, Abigail, et al.
Published: (2005)

Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?
by: Zachary C. Stensland, et al.
Published: (2021-01-01)

Restoration of Noncarious Cervical Lesions: When, Why, and How
by: Cesar dos Reis Perez, et al.
Published: (2012-01-01)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
by: Karthik Ramasamy, et al.
Published: (2023-09-01)

Allergen immunotherapy in Italy: How, when, and why—A real-world study conducted through a patient association
by: Giovanni Paoletti, MD, et al.
Published: (2025-01-01)

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
by: Evangelos Terpos, et al.
Published: (2015-10-01)

Immunotherapy for Multiple Myeloma
by: Nicolaus Kröger, et al.
Published: (2012-01-01)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
by: Thanh-Nhan Nguyen-Pham, et al.
Published: (2012-01-01)

Returning to the scene of the trauma in PTSD treatment – why, how and when?
by: Murray, H, et al.
Published: (2015)

Why, when and how to adjust your p values?
by: Jafari, M, et al.
Published: (2019)

Blood pressure measurement: Why, how, when, and where?
by: E. O'Brien
Published: (2012-04-01)

Bifidobacteria, Lactobacilli... when, how and why to use them
by: Mariarosaria Matera
Published: (2024-06-01)

Notch Signaling in HSC Emergence: When, Why and How
by: Roshana Thambyrajah, et al.
Published: (2022-01-01)

When, How, and Why Did “Pain” Become Subjective?
by: Charles Djordjevic
Published: (2023-06-01)

Very early orthodontic treatment: when, why and how?
by: Ute E. M. SCHNEIDER-MOSER, et al.
Published: (2022-06-01)

Exercise training in chronic heart failure: Why, when and how
by: S Sixt, et al.
Published: (2001-09-01)